Sugi Predict

Sugi Predict / Targets / ZAP70

ZAP70

Tyrosine-protein kinase ZAP-70 · P43403 · ZAP70 on Sugi Atlas →

34,723 patent compounds predicted against ZAP70, 24,415 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL23412 SCHEMBL23412 0.53 11/20
SCHEMBL144714 SCHEMBL144714 0.64 10/20
SCHEMBL140075 SCHEMBL140075 0.56 10/20
SCHEMBL144871 SCHEMBL144871 0.56 10/20
SCHEMBL20561 SCHEMBL20561 0.54 10/20
SCHEMBL141036 SCHEMBL141036 0.53 10/20
SCHEMBL375886 SCHEMBL375886 1.00 9/20
SCHEMBL375523 SCHEMBL375523 0.76 8/20
SCHEMBL381697 SCHEMBL381697 0.76 8/20
SCHEMBL375194 SCHEMBL375194 0.62 8/20
SCHEMBL375360 SCHEMBL375360 0.61 8/20
SCHEMBL375534 SCHEMBL375534 0.65 7/20
SCHEMBL375362 SCHEMBL375362 0.60 7/20
SCHEMBL374077 SCHEMBL374077 0.77 6/20
SCHEMBL375608 SCHEMBL375608 0.71 6/20
SCHEMBL381092 SCHEMBL381092 0.67 6/20
SCHEMBL146914 SCHEMBL146914 0.52 6/20
SCHEMBL413904 SCHEMBL413904 0.47 6/20
SCHEMBL375527 SCHEMBL375527 0.45 6/20
SCHEMBL382124 SCHEMBL382124 0.69 5/20

Clinical trials — most relevant to ZAP70 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia PHASE3ACTIVE_NOT_RECRUITING
Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2COMPLETED
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors PHASE2NOT_YET_RECRUITING
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers PHASE1/PHASE2RECRUITING
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia PHASE2ACTIVE_NOT_RECRUITING
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma PHASE1/PHASE2RECRUITING
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL PHASE2RECRUITING
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma PHASE2UNKNOWN
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors PHASE1RECRUITING
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant PHASE1COMPLETED
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria PHASE1COMPLETED
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) EARLY_PHASE1UNKNOWN
Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML EARLY_PHASE1NOT_YET_RECRUITING
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997 nanCOMPLETED
RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Immunophenotypic Evaluation of IL-7R α in Acute Leukaemia nanUNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ZAP70 binder may also engage these)

ProteinNameSimilarity
P43404 — 1.000 P43404 →
Q64725 — 0.997 Q64725 →
P48025 — 0.994 P48025 →
SYK Tyrosine-protein kinase SYK 0.994 landscape →
Q00655 — 0.993 Q00655 →
F1N9Y5 — 0.990 F1N9Y5 →
TXK Tyrosine-protein kinase TXK 0.989 landscape →
P42682 — 0.988 P42682 →
BMX Cytoplasmic tyrosine-protein kinase BMX 0.988 landscape →
O13147 — 0.987 O13147 →
Q54Y55 — 0.986 Q54Y55 →
Q60629 — 0.985 Q60629 →
P10686 — 0.985 P10686 →
Q54RB7 — 0.985 Q54RB7 →
PLCG1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 0.985 landscape →
Q62077 — 0.984 Q62077 →
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 0.984 landscape →
Q24145 — 0.984 Q24145 →
P70600 — 0.984 P70600 →
P29351 — 0.984 P29351 →
P00528 — 0.984 P00528 →
P97504 — 0.984 P97504 →
P41241 — 0.984 P41241 →
Q64682 — 0.983 Q64682 →
Q8VZD5 — 0.983 Q8VZD5 →
O12990 — 0.983 O12990 →
Q9H1H9 — 0.983 Q9H1H9 →
P08487 — 0.983 P08487 →
Q09639 — 0.983 Q09639 →
P35991 — 0.983 P35991 →